Characterization of Adult Patients With SMA Treated in US Hospital Settings: A Natural History Study in the Premier Healthcare Database.


Journal

Journal of neuromuscular diseases
ISSN: 2214-3602
Titre abrégé: J Neuromuscul Dis
Pays: Netherlands
ID NLM: 101649948

Informations de publication

Date de publication:
2021
Historique:
pubmed: 13 4 2021
medline: 21 12 2021
entrez: 12 4 2021
Statut: ppublish

Résumé

Spinal muscular atrophy (SMA) is a rare genetic disease characterized by progressive muscular weakness and atrophy resulting from motor neuron degeneration. Limited information is available on disease progression among older SMA patients, particularly adults. This study sought to characterize the natural history of SMA among adult patients in US hospital settings through the assessment of symptoms, complications, costs, and healthcare resource utilization (HRU) over 3 years before the availability of disease-modifying therapies. The study population included adult (≥18 years) patients with inpatient and/or hospital-based outpatient discharge records and ≥2 primary or secondary SMA ICD-9 codes ≥30 days apart in the Premier Healthcare Database during the main study period (2007-2014). Index date was the date of the first SMA ICD-9 code. The frequency of SMA-related symptoms and complications was assessed 1 year preindex through 2 years postindex to characterize disease progression. Costs and HRU were also assessed across the study period. A total of 446 adult patients from 337 US hospitals met inclusion criteria for these analyses. All evaluated SMA-related symptoms and complications increased steadily over time, from 1 year preindex to 2 years postindex both overall and in each age group. Adult patients with SMA had increasing total costs and HRU over the 3-year study period: total costs were $1,759 preindex and $12,308 by 2 years postindex. Findings are consistent with increasing disease burden over time and support the progressive nature of SMA for adult patients with hospital interactions.

Sections du résumé

BACKGROUND BACKGROUND
Spinal muscular atrophy (SMA) is a rare genetic disease characterized by progressive muscular weakness and atrophy resulting from motor neuron degeneration. Limited information is available on disease progression among older SMA patients, particularly adults.
OBJECTIVE OBJECTIVE
This study sought to characterize the natural history of SMA among adult patients in US hospital settings through the assessment of symptoms, complications, costs, and healthcare resource utilization (HRU) over 3 years before the availability of disease-modifying therapies.
METHODS METHODS
The study population included adult (≥18 years) patients with inpatient and/or hospital-based outpatient discharge records and ≥2 primary or secondary SMA ICD-9 codes ≥30 days apart in the Premier Healthcare Database during the main study period (2007-2014). Index date was the date of the first SMA ICD-9 code. The frequency of SMA-related symptoms and complications was assessed 1 year preindex through 2 years postindex to characterize disease progression. Costs and HRU were also assessed across the study period.
RESULTS RESULTS
A total of 446 adult patients from 337 US hospitals met inclusion criteria for these analyses. All evaluated SMA-related symptoms and complications increased steadily over time, from 1 year preindex to 2 years postindex both overall and in each age group. Adult patients with SMA had increasing total costs and HRU over the 3-year study period: total costs were $1,759 preindex and $12,308 by 2 years postindex.
CONCLUSIONS CONCLUSIONS
Findings are consistent with increasing disease burden over time and support the progressive nature of SMA for adult patients with hospital interactions.

Identifiants

pubmed: 33843692
pii: JND200624
doi: 10.3233/JND-200624
pmc: PMC8385506
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

569-578

Références

Spine (Phila Pa 1976). 2011 Apr 20;36(9):731-6
pubmed: 20881515
Orphanet J Rare Dis. 2017 Jul 4;12(1):124
pubmed: 28676062
Neurology. 2018 Sep 25;91(13):e1206-e1214
pubmed: 30143566
Lancet. 2008 Jun 21;371(9630):2120-33
pubmed: 18572081
Int J Epidemiol. 1987 Dec;16(4):537-44
pubmed: 3501989
Am J Hum Genet. 2002 Feb;70(2):358-68
pubmed: 11791208
Eur Spine J. 2016 Oct;25(10):3082-3087
pubmed: 26329652
Proc Natl Acad Sci U S A. 1999 May 25;96(11):6307-11
pubmed: 10339583
Otolaryngol Head Neck Surg. 2014 Nov;151(5):765-9
pubmed: 25193514
Orphanet J Rare Dis. 2017 Nov 28;12(1):175
pubmed: 29183396
Pharmacoecon Open. 2019 Jun;3(2):205-213
pubmed: 30182345
Neuromuscul Disord. 2015 Jul;25(7):593-602
pubmed: 26045156
Cell. 1995 Jan 13;80(1):155-65
pubmed: 7813012
Hum Mol Genet. 1999 Jul;8(7):1177-83
pubmed: 10369862
Natl Vital Stat Rep. 2019 Jun;68(9):1-77
pubmed: 32501199
Pediatr Neurol. 2019 Mar;92:3-5
pubmed: 30591237
N Engl J Med. 2015 Dec 10;373(24):2382
pubmed: 26650159
J Med Econ. 2020 Jan;23(1):70-79
pubmed: 31322019
Arch Neurol. 1995 May;52(5):518-23
pubmed: 7733848

Auteurs

Nicole B Johnson (NB)

Biogen, Cambridge, MA, USA.

Crystal Proud (C)

Children's Hospital of The King's Daughters, Norfolk, VA, USA.

Christina L Wassel (CL)

Premier Inc., Charlotte, NC, USA.

Jill Dreyfus (J)

Premier Inc., Charlotte, NC, USA.

Thos Cochrane (T)

Biogen, Cambridge, MA, USA.

Angela D Paradis (AD)

Biogen, Cambridge, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH